CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials

May 29-June 2, 2015; Chicago, Illinois
Results of a prospectively designed meta-analysis of a new surrogate endpoint that may expedite patient access to effective new therapies.
Format: Microsoft PowerPoint (.ppt)
File Size: 387 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slides on most current clinical data on treating patients with BTK inhibitors

Ian W. Flinn, MD, PhD Released: December 6, 2019

From Clinical Care Options (CCO), preview key PTCL studies to be presented at ASH 2019, as selected by experts

Barbara Pro, MD Released: December 6, 2019

Downloadable slides on most current clinical data on treating patients with BTK inhibitors

John Pagel Headshot John Pagel, MD, PhD Released: December 6, 2019

Downloadable slides on most current clinical data on treating patients with BTK inhibitors

Jan A. Burger, MD, PhD Released: December 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?